NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+13.95%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$227M
AUM Growth
+$227M
(+22%)
Cap. Flow
+$29.3M
Cap. Flow
% of AUM
12.91%
Top 10 Holdings %
Top 10 Hldgs %
56.37%
Holding
55
New
14
Increased
8
Reduced
9
Closed
18
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$20.3M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$15.2M |
| 3 |
Sangamo Therapeutics
SGMO
|
$11.7M |
| 4 |
FibroGen
FGEN
|
$11.7M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
$11.1M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$12.9M |
| 2 |
Pfizer
PFE
|
$11.8M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$10.4M |
| 4 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$9.78M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.09M |
Sector Composition
| 1 | Healthcare | 85.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $20.3M | 5.22% | +373,000 | New | +$20.3M |
|
|
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
| $15.2M | 3.91% | +184,680 | New | +$15.2M |
|
3
GSK
GSK
$79.9B
| $14.5M | 3.74% | 358,053 +36,053 | +11% | +$1.46M |
|
|
4
Sangamo Therapeutics
SGMO
$157M
| $11.7M | 3.01% | +781,000 | New | +$11.7M |
|
|
5
FibroGen
FGEN
$47.8M
| $11.7M | 3.01% | +217,329 | New | +$11.7M |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $11.1M | 2.86% | 119,661 +18,861 | +19% | +$1.76M |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $11.1M | 2.85% | +792,106 | New | +$11.1M |
|
8
Aclaris Therapeutics
ACRS
$209M
| $10.7M | 2.76% | 416,312 +76,312 | +22% | +$1.97M |
|
|
SHPG
9
DELISTED
Shire pic
SHPG
| $10.7M | 2.74% | 69,648 -31,852 | -31% | -$4.88M |
|
|
DOVA
10
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $10.6M | 2.74% | 438,119 +240,060 | +121% | +$5.83M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $9.37M | 2.41% | 79,772 -25,228 | -24% | -$2.96M |
|
|
AKAO
12
DELISTED
Achaogen, Inc.
AKAO
| $9.22M | 2.37% | +577,766 | New | +$9.22M |
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $8.75M | 2.25% | 62,337 -57,663 | -48% | -$8.09M |
|
|
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $8.39M | 2.16% | 270,075 -70,025 | -21% | -$2.17M |
|
|
IPXL
15
DELISTED
Impax Laboratories, Inc.
IPXL
| $8.17M | 2.1% | 402,404 -157,996 | -28% | -$3.21M |
|
|
ARRY
16
DELISTED
Array Biopharma Inc
ARRY
| $7.57M | 1.95% | +615,437 | New | +$7.57M |
|
|
FLXN
17
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $6.56M | 1.69% | 271,136 +40,636 | +18% | +$983K |
|
|
PRTK
18
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $6.08M | 1.56% | 242,300 +192,300 | +385% | +$4.83M |
|
19
Supernus Pharmaceuticals
SUPN
$2.53B
| $5.29M | 1.36% | +132,270 | New | +$5.29M |
|
|
CBIO
20
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $4.5M | 1.16% | +321,286 | New | +$4.5M |
|
21
Insmed
INSM
$28.8B
| $4.49M | 1.16% | 144,000 -16,000 | -10% | -$499K |
|
22
Minerva Neurosciences
NERV
$16.5M
| $4.08M | 1.05% | 536,899 -38,101 | -7% | -$290K |
|
23
Kura Oncology
KURA
$686M
| $3.87M | 0.99% | +258,516 | New | +$3.87M |
|
|
RXDX
24
DELISTED
Ignyta, Inc.
RXDX
| $3.53M | 0.91% | 285,728 +35,728 | +14% | +$441K |
|
|
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $3.52M | 0.91% | 600,000 +100,000 | +20% | +$587K |
|